BioSpace News Archive

Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced that the ASTONISH Independent Data Monitoring Committee completed the planned safety and efficacy assessment for futility of the company’s ongoing Phase IIB ASTONISH trial in septic shock patients.

MannKind Corporation and Thirona Bio, Inc. announced that they have entered into a transaction that is intended to advance the development of a novel compound with potential for multiple indications.

ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, announced that Company management will present during a fireside chat at the upcoming JMP Securities Life Sciences Conference.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced the launch of its 6.5mm/7.3mm Slipped Capital Femoral Epiphysis Cannulated Screw system.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the BIO Digital Conference being held June 10-11 and 14-18, 2021.

Baudax Bio, Inc. announced Gerri Henwood, the Company’s President and Chief Executive Officer, will participate in a fireside chat virtually at the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 4:00 p.m. ET.

Tyme Technologies, Inc. (Nasdaq:TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today reported its conclusions from its recently conducted comprehensive strategic review and its fourth quarter and fiscal year 2021 financial results.

Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Raymond James Human Health Innovation Conference 2021 to be held virtually on Monday, June 21, 2021.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of the pediatric indication of Epclusa® (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C virus (HCV) to now include children as young as 3 years of age, regardless of HCV genotype or liver disease severity

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that multiple presentations highlighting advances in its ATTR amyloidosis programs will be featured during the 2021 Peripheral Nerve Society (PNS) Annual Meeting to be held virtually on June 12-13, and 25-27, 2021.